The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antibody-drug Conjugate for Cancer Market Research Report 2025
Synopsis
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
The global Antibody-drug Conjugate for Cancer market was valued at US$ 849.4 million in 2023 and is anticipated to reach US$ 1179.4 million by 2030, witnessing a CAGR of 4.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibody-drug Conjugate for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-drug Conjugate for Cancer.
Report Scope
The Antibody-drug Conjugate for Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody-drug Conjugate for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody-drug Conjugate for Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead Sciences
Roche
Pfizer
Takeda
Seagen
Innate Pharma
AstraZeneca
GSK
Rakuten Medical
Segment by Type
Hematological Malignancies Drugs
Solid Tumor Drugs
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody-drug Conjugate for Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
The global Antibody-drug Conjugate for Cancer market was valued at US$ 849.4 million in 2023 and is anticipated to reach US$ 1179.4 million by 2030, witnessing a CAGR of 4.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibody-drug Conjugate for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-drug Conjugate for Cancer.
Report Scope
The Antibody-drug Conjugate for Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody-drug Conjugate for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody-drug Conjugate for Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead Sciences
Roche
Pfizer
Takeda
Seagen
Innate Pharma
AstraZeneca
GSK
Rakuten Medical
Segment by Type
Hematological Malignancies Drugs
Solid Tumor Drugs
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody-drug Conjugate for Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody-drug Conjugate for Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Hematological Malignancies Drugs
1.2.3 Solid Tumor Drugs
1.3 Market by Application
1.3.1 Global Antibody-drug Conjugate for Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody-drug Conjugate for Cancer Market Perspective (2019-2030)
2.2 Antibody-drug Conjugate for Cancer Growth Trends by Region
2.2.1 Global Antibody-drug Conjugate for Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antibody-drug Conjugate for Cancer Historic Market Size by Region (2019-2024)
2.2.3 Antibody-drug Conjugate for Cancer Forecasted Market Size by Region (2025-2030)
2.3 Antibody-drug Conjugate for Cancer Market Dynamics
2.3.1 Antibody-drug Conjugate for Cancer Industry Trends
2.3.2 Antibody-drug Conjugate for Cancer Market Drivers
2.3.3 Antibody-drug Conjugate for Cancer Market Challenges
2.3.4 Antibody-drug Conjugate for Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody-drug Conjugate for Cancer Players by Revenue
3.1.1 Global Top Antibody-drug Conjugate for Cancer Players by Revenue (2019-2024)
3.1.2 Global Antibody-drug Conjugate for Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Antibody-drug Conjugate for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antibody-drug Conjugate for Cancer Revenue
3.4 Global Antibody-drug Conjugate for Cancer Market Concentration Ratio
3.4.1 Global Antibody-drug Conjugate for Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody-drug Conjugate for Cancer Revenue in 2023
3.5 Antibody-drug Conjugate for Cancer Key Players Head office and Area Served
3.6 Key Players Antibody-drug Conjugate for Cancer Product Solution and Service
3.7 Date of Enter into Antibody-drug Conjugate for Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody-drug Conjugate for Cancer Breakdown Data by Type
4.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Type (2019-2024)
4.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Type (2025-2030)
5 Antibody-drug Conjugate for Cancer Breakdown Data by Application
5.1 Global Antibody-drug Conjugate for Cancer Historic Market Size by Application (2019-2024)
5.2 Global Antibody-drug Conjugate for Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antibody-drug Conjugate for Cancer Market Size (2019-2030)
6.2 North America Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024)
6.4 North America Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody-drug Conjugate for Cancer Market Size (2019-2030)
7.2 Europe Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024)
7.4 Europe Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size (2019-2030)
8.2 Asia-Pacific Antibody-drug Conjugate for Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Antibody-drug Conjugate for Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody-drug Conjugate for Cancer Market Size (2019-2030)
9.2 Latin America Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024)
9.4 Latin America Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size (2019-2030)
10.2 Middle East & Africa Antibody-drug Conjugate for Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Antibody-drug Conjugate for Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Detail
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences Antibody-drug Conjugate for Cancer Introduction
11.1.4 Gilead Sciences Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.1.5 Gilead Sciences Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Antibody-drug Conjugate for Cancer Introduction
11.2.4 Roche Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Antibody-drug Conjugate for Cancer Introduction
11.3.4 Pfizer Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Takeda
11.4.1 Takeda Company Detail
11.4.2 Takeda Business Overview
11.4.3 Takeda Antibody-drug Conjugate for Cancer Introduction
11.4.4 Takeda Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.4.5 Takeda Recent Development
11.5 Seagen
11.5.1 Seagen Company Detail
11.5.2 Seagen Business Overview
11.5.3 Seagen Antibody-drug Conjugate for Cancer Introduction
11.5.4 Seagen Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.5.5 Seagen Recent Development
11.6 Innate Pharma
11.6.1 Innate Pharma Company Detail
11.6.2 Innate Pharma Business Overview
11.6.3 Innate Pharma Antibody-drug Conjugate for Cancer Introduction
11.6.4 Innate Pharma Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.6.5 Innate Pharma Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Antibody-drug Conjugate for Cancer Introduction
11.7.4 AstraZeneca Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.7.5 AstraZeneca Recent Development
11.8 GSK
11.8.1 GSK Company Detail
11.8.2 GSK Business Overview
11.8.3 GSK Antibody-drug Conjugate for Cancer Introduction
11.8.4 GSK Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.8.5 GSK Recent Development
11.9 Rakuten Medical
11.9.1 Rakuten Medical Company Detail
11.9.2 Rakuten Medical Business Overview
11.9.3 Rakuten Medical Antibody-drug Conjugate for Cancer Introduction
11.9.4 Rakuten Medical Revenue in Antibody-drug Conjugate for Cancer Business (2019-2024)
11.9.5 Rakuten Medical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
